Business Wire

The O-RAN ALLIANCE Announces the 5 th Release of Its Open Source Software and An Industry Briefing at MWC Barcelona

Share

O-RAN ALLIANCE:

O-RAN ALLIANCE Industry Briefing, March 1, 2022 at MWC Barcelona

O-RAN ALLIANCE plans to hold its next industry event on March 1, 2022 from 17:15-18:00 CET, hosted at the Deutsche Telekom booth at MWC Barcelona 2022, Hall 3 Stand 3M31. The event will include keynotes from O-RAN ALLIANCE’s leadership and an industry panel discussion.

Save the date and follow our website for further updates.

5th Release of Open Software for the RAN – “E” – Delivered by the O-RAN Software Community

The O-RAN Software Community (OSC or O-RAN SC) was formed in partnership with the Linux Foundation in April 2019, to support software development of open RAN solutions available to everyone.

In December 2021, following on the half year release cycle, the OSC published its 5th open software release dubbed "E". The E release further enhances the traffic steering use case, introduces basic RAN slicing feature and closed loop slice SLA assurance. With these enhanced features and the end-to-end integration of O-RAN architecture components, the E release moves the O-RAN ecosystem one step closer to commercial deployments in mobile networks around the globe.

The main use cases and features delivered in the E release include:

  • Slicing-related 3GPP-compliant Performance Measurement (PM) events, which are supported by the O-RAN Service Management and Orchestration (SMO) framework
  • O1 Simulator for slicing support
  • Two simplified rApps for close loop O-RU recovery and O-DU slicing assurance added to the Non-Real-Time Radio Intelligent Controller (Non-RT RIC) software
  • Improved E2 interface Application Protocol (E2AP) software implementation according to updated O-RAN Near-Real-time RIC (Near-RT RIC) E2AP specification version 1.1
  • A new RAN Control (RC) xApp added to the Near-RT RIC, which implements a subset of the new E2 Service Management RC to support traffic steering end to end use case
  • Software implementation of the O-Cloud reference design and O2 interface defined in O-RAN ALLIANCE’s Minimum Viable Plan (MVP)
  • O1/Virtual Event Streaming (VES) disaggregation
  • Multi UE and Multi Bearer support

To deep-dive into the E release and to get the open software, please visit the O-RAN Software Community website.

"In addition to the continuous enhancement on the Traffic Steering use case, I am glad to see the community march in a significant way forward by starting the support of Network Slicing. For this, we are thankful to the joint efforts from all the contributors," said Chih-Lin I, the co-chair of O-RAN Technical Steering Committee. "Equally significant, we have established two additional open labs for open source software test and integration, which will further accelerate our feature implementation and delivery activities in the future."

“With Release E, Nokia continues to demonstrate its commitment to O-RAN and advance the maturity of O-RAN specifications,” said Pasi Toivanen, Head of Edge Cloud at Nokia. “This work is supported by Nokia’s open-source contributions to the O-RAN software community Near-Real-Time Radio Intelligent Controller platform, with the simplified REST-based interface for xApps to manage O-RAN E2 subscriptions as well as additional functionality in the xApp framework SDKs, including also the SDL (Shared Data Layer) APIs.”

“We are excited to assist the OSC's delivery of its industry-leading fifth software release, with an expanded slate of applications (xApps) and Interfaces, in alignment with O-RAN specifications," said Arpit Joshipura, general manager, Networking, Edge, and IoT, the Linux Foundation.

“It is exciting to be part of the major steps forward in O-RAN over the last few months. With the support of our business partners, highstreet technologies continues to advance the O1/OAM capability for both O-RAN and OSC. And in 2022 we will have the opportunity to showcase to the world the full benefits of the disaggregated O-RAN architecture when deployed for Small-Medium Enterprise users,” said Alfons Mittermaier, Managing Director of highstreet technologies.

“The growth of the O-RAN Software Community has been remarkable. With the O-RAN SC E release, this milestone will help to further accelerate O-RAN globally and advance the deployment of flexible networks demanding carrier-grade cloud-native infrastructure as we move towards an intelligent systems world fueled by innovative edge applications,” said Gil Hellmann, vice president, Telecom Solutions Engineering, Wind River. “In O-RAN SC E release, Wind River has continued with key contributions to the INF project by enabling more open RAN related features, implementing a framework supporting O2 interface which is pivotal to the cloud infrastructure management and deployment operations.”

“HCL is glad to be a part of the O-RAN ALLIANCE and has significantly contributed to several O-RAN Software Community (OSC) projects. Our collaboration with the OSC aligns with HCL’s Mode 2 strategy of accelerating new Digital Engineering services by leveraging next generation 5G technologies. HCL has made important contributions to the E-release of OSC’s Open software around the hardening of the RAN Intelligent Controller (RIC) platform, InfluxDB SDL integration, ODU High O1 support for the closed-loop slice SLA assurance automation use case, and 4 xApps (Near-Real-Time RIC Apps). HCL looks forward to further contribution on realizing a Minimum Viable Plan (MVP) from the OSC,” said Rajiv Shesh, Corporate VP, Engineering and R&D Services, HCL Technologies.

About O-RAN ALLIANCE

The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information please visit www.o-ran.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of